Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
1
17%
Ph phase_4
2
33%
Ph phase_3
1
17%
Ph early_phase_1
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
2(33.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 42 (33.3%)
N/A1 (16.7%)

Trials by Status

unknown117%
terminated117%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_4

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

NCT03660683
completedphase_2

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

NCT03714594
completedphase_4

Tubular Markers in Response to Saxagliptin Therapy

NCT04521049
unknownnot_applicable

Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy Volunteers

NCT04170790
completedearly_phase_1

Neuropeptide Y and Sympathovagal Balance

NCT03933787
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03660683Phase 4

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

Terminated
NCT03714594Phase 2

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

Completed
NCT04521049Phase 4

Tubular Markers in Response to Saxagliptin Therapy

Completed
NCT04170790Not Applicable

Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy Volunteers

Unknown
NCT03933787Early Phase 1

Neuropeptide Y and Sympathovagal Balance

Completed
NCT02104804Phase 3

Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6